TrialCurveCPT-MM301: reconstructed Kaplan–Meier curves
Aponermin or placebo in combination with thalidomide and dexamethasone in the treatment of relapsed or refractory multiple myeloma (CPT-MM301): a randomised, double-blinded, placebo-controlled, phase 3 trial. Curves rebuilt as patient-level data (Guyot 2012) and checked against the statistics printed on the figure.
| Publication | BMC Cancer. 2023 Oct 14;23:980. doi: 10.1186/s12885-023-11489-8 |
|---|---|
| DOI | 10.1186/s12885-023-11489-8 |
| Registry | — |
| Phase | — |
| Conditions | — |
| Interventions | — |
| Sponsor | — |
| Enrolment | — |
| Source licence | Figure published under CC BY 4.0 |
Progression-free survival (Independent Assessment Committee) — Modified intention-to-treat population
From figure panel A · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: Aponermin Group 5.5 months; Placebo Group 3.1 months. Survival at 12 months: Aponermin Group 28%; Placebo Group 14%. Hazard ratio Aponermin Group vs Placebo Group 0.62 (95% CI 0.49–0.79).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| Aponermin Group | 276 | 205 | 5.5 |
| Placebo Group | 139 | 112 | 3.1 |
- Aponermin Group vs Placebo Group: reconstructed HR 0.62 (95% CI 0.49–0.79)
Landmark survival (reconstructed)
| Time | Aponermin Group | Placebo Group |
|---|---|---|
| 6 mo | 46.5% | 26.7% |
| 12 mo | 27.8% | 14.2% |
| 18 mo | 20.6% | 10.0% |
| 24 mo | 8.8% | 5.0% |
Checks against the published figure
- Aponermin Group median: printed 5.5, reconstructed 5.46 pass
- Placebo Group median: printed 3.1, reconstructed 3.15 pass
- hazard ratio (direction inferred): printed 0.62, reconstructed 0.623 pass
Overall survival — Modified intention-to-treat population (all patients who received at least one dose of trial treatment)
From figure panel A · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: Aponermin Group 22.3 months; Placebo Group 16.2 months. Survival at 18 months: Aponermin Group 55%; Placebo Group 49%. Hazard ratio Aponermin Group vs Placebo Group 0.73 (95% CI 0.58–0.93).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| Aponermin Group | 276 | 191 | 22.3 |
| Placebo Group | 139 | 113 | 16.2 |
- Aponermin Group vs Placebo Group: reconstructed HR 0.73 (95% CI 0.58–0.93)
Landmark survival (reconstructed)
| Time | Aponermin Group | Placebo Group |
|---|---|---|
| 6 mo | 84.4% | 74.1% |
| 12 mo | 67.8% | 59.0% |
| 18 mo | 55.4% | 48.7% |
| 24 mo | 48.5% | 36.0% |
| 36 mo | 30.6% | 23.0% |
| 48 mo | 23.6% | 14.3% |
| 60 mo | 22.8% | 10.7% |
Checks against the published figure
- Aponermin Group median: printed 22.4, reconstructed 22.3 pass
- Placebo Group median: printed 16.4, reconstructed 16.2 pass
- hazard ratio (direction inferred): printed 0.7, reconstructed 0.734 pass
About these data
Pseudo-IPD reproduces the published curves and numbers at risk; the rows are not real patients. Cite the publication (DOI above) and TrialCurve. The source figure is © the authors (CC BY 4.0); the charts here are redrawn from the reconstruction.
Related trials
- CEPHEUS: Overall survival; Progression-free survival
- Mesenchymal stromal cells for steroid-resistant acute GVHD: Cumulative incidence of leukemia relapse; Non-relapse mortality (NRM); Overall survival; c
- ADMYRE: Overall survival; Progression-free survival with PD confirmation by investigator's assessm
- CLL12: Event-free survival (EFS); Overall survival (OS)
- Acalabrutinib vs chlorambucil + rituximab in CLL (Asian phase 3): BICR-assessed duration of response; BICR-assessed progression-free survival; Overall survi
Need reconstructed data for other trials? Upload any Kaplan–Meier figure, or ask about the TrialCurve oncology library.
Reconstruct a figure Browse all trials